Diversified Trust Co Sells 2,273 Shares of West Pharmaceutical Services, Inc. $WST

Diversified Trust Co decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 47.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,478 shares of the medical instruments supplier’s stock after selling 2,273 shares during the quarter. Diversified Trust Co’s holdings in West Pharmaceutical Services were worth $621,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. CYBER HORNET ETFs LLC purchased a new stake in West Pharmaceutical Services during the second quarter valued at about $25,000. Elyxium Wealth LLC bought a new stake in West Pharmaceutical Services during the fourth quarter worth about $25,000. Bayban purchased a new position in shares of West Pharmaceutical Services in the 4th quarter worth about $27,000. Private Trust Co. NA boosted its holdings in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares in the last quarter. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $28,000. 93.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $347.34 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services, Inc. has a fifty-two week low of $206.80 and a fifty-two week high of $352.31. The stock has a 50 day moving average price of $312.15 and a two-hundred day moving average price of $275.06. The company has a market capitalization of $24.54 billion, a P/E ratio of 46.44, a PEG ratio of 2.85 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.67 million. During the same quarter in the prior year, the firm posted $1.45 earnings per share. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Morgan Stanley boosted their price objective on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the stock an “equal weight” rating in a report on Friday, May 29th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $340.09.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.